Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases

被引:91
作者
Darson, MF
Pacelli, A
Roche, P
Ritttenhouse, HG
Wolfert, RL
Saeid, MS
Young, CYF
Klee, GG
Tindall, DJ
Bostwick, DG
机构
[1] Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Urol, Rochester, MN 55905 USA
[3] Hybritech Inc, San Diego, CA USA
关键词
D O I
10.1016/S0090-4295(98)00637-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To describe the expression of a potential new tumor marker, human glandular kallikrein 2 (hK2), in primary adenocarcinoma and lymph node metastases that may be useful as an adjunct to prostate-specific antigen (PSA) in the diagnosis and monitoring of prostate cancer. Methods, We evaluated 151 radical prostatectomy specimens removed at Mayo Clinic with node-positive adenocarcinoma to compare cytoplasmic expression of hK2, pro-hK2, and PSA in benign tissue, prostate adenocarcinoma, and lymph node metastases. Monoclonal antibodies for mature hK2 (hK2-G586), pro-hK2 (pro-hK2-G464), and PSA (PSA-773) were used. A polyclonal antibody for PSA was also used. Immunoreactivity in each case was tested to determine whether cancer recurrence could be predicted. Results. Intense epithelial cytoplasmic immunoreactivity was observed in every case for hK2-G586, pro-hK2-G464, PSA-773, and polyclonal PSA (100% of cases, respectively). The intensity and extent of hK2 expression was greater in lymph node metastases than in primary cancer; furthermore, the expression in primary cancer was greater than in benign epithelium. Pro-hK2 was expressed in a greater percentage of cells in primary cancer than in benign tissue; furthermore, pro-hK2 was expressed to a greater extent in primary cancer than in lymph node metastases. In marked contrast to mature hK2, monoclonal PSA immunoreactivity was expressed to a higher extent in primary cancer than in lymph node metastases. Polyclonal PSA showed an incremental increase in expression from benign tissue to primary cancer and a further increase in expression in lymph node metastases. Conclusions. hK2 was expressed in every cancer, and the expression incrementally increased from benign epithelium to primary cancer and lymph node metastases. Pro-hK2 was expressed to the greatest extent in primary cancer. Monoclonal PSA displayed inverse immunoreactivity compared with hK2, Polyclonal PSA showed incremental increases, suggesting that both hK2 and PSA were being detected. Tissue expression of hK2 appears to be regulated independently of PSA in benign epithelium, adenocarcinoma, and lymph node metastases, UROLOGY 53: 939-944, 1999. (C) 1999, Elsevier Science Inc. All rights reserved.
引用
收藏
页码:939 / 944
页数:6
相关论文
共 25 条
  • [1] BOSTWICK DG, 1995, CANCER-AM CANCER SOC, V75, P1823, DOI 10.1002/1097-0142(19950401)75:7+<1823::AID-CNCR2820751612>3.0.CO
  • [2] 2-7
  • [3] Bostwick DG, 1996, PROSTATE, V29, P117
  • [4] Measurement of complexed PSA improves specificity for early detection of prostate cancer
    Brawer, MK
    Meyer, GE
    Letran, JL
    Bankson, DD
    Morris, DL
    Yeung, KK
    Allard, WJ
    [J]. UROLOGY, 1998, 52 (03) : 372 - 378
  • [5] CATALONA WJ, 1995, JAMA-J AM MED ASSOC, V274, P1214
  • [6] HIGH-LEVEL OF EXPRESSION IN THE PROSTATE OF A HUMAN GLANDULAR KALLIKREIN MESSENGER-RNA RELATED TO PROSTATE-SPECIFIC ANTIGEN
    CHAPDELAINE, P
    PARADIS, G
    TREMBLAY, RR
    DUBE, JY
    [J]. FEBS LETTERS, 1988, 236 (01) : 205 - 208
  • [7] Charlesworth MC, 1997, UROLOGY, V49, P487
  • [8] COHEN RJ, 1994, ARCH PATHOL LAB MED, V118, P1123
  • [9] SILVER-STAINED STRUCTURES IN PROSTATIC-CARCINOMA - EVALUATION OF DIAGNOSTIC AND PROGNOSTIC RELEVANCE BY AUTOMATED IMAGE-ANALYSIS
    CONTRACTOR, H
    RUSCHOFF, J
    HANISCH, T
    ULSHOFER, B
    NEUMANN, K
    SCHULTZESEEMANN, W
    THOMAS, C
    [J]. UROLOGIA INTERNATIONALIS, 1991, 46 (01) : 9 - 14
  • [10] Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker
    Darson, MF
    Pacelli, A
    Roche, P
    Rittenhouse, HG
    Wolfert, RL
    Young, CYF
    Klee, GG
    Tindall, DJ
    Bostwick, DG
    [J]. UROLOGY, 1997, 49 (06) : 857 - 862